DailyIQ
Last updatedUpdating…

RPRX·Royalty Pharma plc

$58.72
+0.31 (+0.53%)
High
$59.07
Open
$58.55
Market Cap
33.59B
52W High
$64.38
Low
$57.82
P. Close
$58.72
P/E
41.21
52W Low
$34.63
Fwd P/E
10.24
DailyIQ Est.
$66.12
Inst. Ownership
30.9%
Short Interest
2.09%
Days to Cover
5.0
Technical Score (1D)
41
SELL
News Sentiment
56
BULLISH
RPRX is printing 41 with NEUTRAL on the 1D view - a classic bearish stall where compressed conditions frustrate breakout traders. Sentiment at 56 is diverging from the indecision, reinforcing a wait-and-see tone. A sustained move beyond $61.05 or under $56.35 would reset the discussion. The longer RPRX sits between $56.35 and $61.05 without resolving, the more energy tends to build for whichever direction eventually wins out. That's not a reason to anticipate the break - it's a reason to have orders ready on both sides so the reaction, whenever it comes, doesn't get missed entirely.
Earnings Summary
Royalty Pharma is a New York‑based investment firm that acquires royalty interests in marketed biopharmaceuticals and provides development funding, giving it exposure to a diversified portfolio of 35 marketed therapies and 14 development candidates across oncology, rare diseases and infectious diseases. Operating within the broader healthcare biotechnology sector, the company’s revenue is driven by royalty receipts rather than product sales. In Q4 2024 Royalty reported EPS of $1.1511 versus an estimate of $1.05403, with revenue of $742 million, while Q4 2025 saw EPS rise to $1.46 against an estimate of $1.15 and revenue of $874 million versus an estimate of $859 million, indicating a modest acceleration in both earnings and top line. Q1 2026 EPS of $1.30 fell slightly below the $1.2368 estimate, and revenue of $925 million was well below the $1.26 billion estimate, reflecting a deceleration; however, Q2 2026 EPS of $1.32 beat the $1.3031 estimate and revenue of $773 million exceeded the $707 million estimate, showing a rebound. Historically, Royalty has posted year‑over‑year revenue growth of roughly 14 % in Q2 2026, with consistent EPS beats in three of the last four quarters, underscoring a pattern of strong earnings performance even when revenue forecasts are conservative. Recent news highlights a setback with Novartis’s pelacarsen Phase 3 trial failure, which could reduce future royalty income, but the company offset this risk with a $100 million upfront payment from Zealand Pharma for rusfertide royalties, providing a new long‑term revenue stream and liquidity boost. The firm also raised its 2026 full‑year guidance following Q2 results, citing a shift toward higher‑IRR development assets and a projected 7‑10 % royalty growth, reinforcing confidence in its diversified portfolio. Investors should watch the upcoming medical congress for pelacarsen data, monitor milestone triggers from the rusfertide deal, and track any adjustments to the 2026 guidance, as these factors will shape Royalty’s near‑term cash‑flow trajectory and valuation outlook.

EPS

EstBeatMiss
$0.99$1.13$1.26$1.39$1.52Q4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.18 - -
Q2'26$1.30$1.32+1.3%
Q1'26$1.24$1.30+5.1%
Q4'25$1.15$1.46+27.0%
Q4'24$1.05$1.15+9.2%

Revenue

EstBeatMiss
$624M$804M$983M$1.2B$1.3BQ4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$860M - -
Q2'26$707M$773M+9.3%
Q1'26$1.3B$925M-26.6%
Q4'25$859M$874M+1.7%
Q4'24 - $742M -

Market Data

RPRX Stock Snapshot

HOLD41/100
$58.72+$0.31 (0.5%)
Market cap
33.59B
P/E ratio
41.2
Day range
$57.82 – $59.07
News sentiment
56/100 · Neutral
Analyst target
$65.12 (+10.9%)
Consensus
Buy · 18 analysts
52-week range+69.6% off low · -8.8% from high
$34.63$64.38
Price $58.72 DailyIQ Est. $66.12

Neither side has the upper hand on RPRX right now, and the indicator set reflects that. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What RPRX's own history says about today's numbers

Realized volatility (21d)
36.5% 83rd pct
Below its peak
-8.1%
vs 200-day average
+16.9%
Up days (1y)
53%

Royalty Pharma plc is currently running 36.5% annualised volatility over the last 21 sessions. Measured against RPRX's own 6 years of daily returns rather than a market-wide average, that is the 83rd percentile elevated for this stock, against a typical reading of 27.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RPRX is trading -8.1% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -21.7%, and the deepest was -34.1% in 2023. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +16.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 84th percentile a wider gap than this stock usually carries. Over the past year RPRX closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On September specifically: over 7 years of records, RPRX finished the month higher 1 of 7 times, with a median return of -4.2% and an average of -3.7%. Its strongest month historically has been January at +5.3% on average, its weakest September at -3.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RPRX has opened more than 2% away from the prior close in 140 of 1,574 sessions (8.9% of the time), with the largest gaps running +8.0% and -6.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, RPRX moved an average of 0.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.4% and a largest of +1.2%.

All figures computed from 1,575 daily closes between 2020-06-16 and 2026-09-21, split-adjusted, recomputed daily. Percentiles are against RPRX's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RPRX's sector?

Royalty Pharma plc sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 11
Sector state
Improving
Sector rotation score
80

Options Market

What is the options market pricing for RPRX?

CallsPuts

For Royalty Pharma plc's nearest expiry (2026-10-16, 25 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.05), with at-the-money implied volatility around 69.0%. The options market is pricing roughly a ±12.8% move by that expiry — a range of about $51.19–$66.25.

Put/call ratio (2026-10-16)
0.05
ATM implied volatility
69.0%
Total open interest
1,409
Expected move by 2026-10-16
±12.8% ($51.19–$66.25)

Analyst Rating Changes

Are analysts turning bullish or bearish on RPRX?

TD Cowen most recently reiterated its rating on Royalty Pharma plc to Buy on Sep 8, 2026 with a price target of $68 (from $65). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
TD CowenBuy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 8, 2026TD CowenMaintainedBuy$65 → $68
Aug 7, 2026JP MorganMaintainedOverweight$58 → $62
Jul 13, 2026TD CowenMaintainedBuy$50 → $65
May 7, 2026CitigroupMaintainedBuy$50 → $66
May 7, 2026JP MorganMaintainedOverweight$50 → $58
Apr 21, 2026UBSMaintainedBuy$51 → $57
Apr 10, 2026Morgan StanleyMaintainedOverweight$61 → $63
Jan 30, 2026UBSUpgradeNeutral → Buy$38 → $49
Jan 27, 2026CitigroupMaintainedBuy$48 → $50
Dec 11, 2025TD CowenMaintainedBuy$42 → $45
Oct 10, 2025Morgan StanleyMaintainedOverweight$55 → $54
Sep 30, 2025Goldman SachsInitiatedBuy$42

RPRX Competitive Positioning

Royalty Pharma plc (RPRX) is tracked alongside these names in Biotechnology on DailyIQ — ranked by market cap, with today's move alongside.